Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-rearrangement”

45 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 45 results

Early research (Phase 1)Looking for participantsNCT05544019
What this trial is testing

Study of SGR-1505 in Mature B-Cell Neoplasms

Who this might be right for
Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more
Schrödinger, Inc. 98
Early research (Phase 1)Active Not RecruitingNCT03707938
What this trial is testing

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung CarcinomaALK Gene RearrangementLung Non-Small Cell Carcinoma+4 more
M.D. Anderson Cancer Center 35
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Testing effectiveness (Phase 2)WithdrawnNCT05718297
What this trial is testing

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Who this might be right for
NSCLC, Stage IIIALK-rearrangement
ETOP IBCSG Partners Foundation
Testing effectiveness (Phase 2)Looking for participantsNCT06834373
What this trial is testing

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Who this might be right for
Large B-Cell Lymphoma With IRF4 RearrangementRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent ALK-Positive Large B-Cell Lymphoma+28 more
Mayo Clinic 41
Not applicableLooking for participantsNCT05724004
What this trial is testing

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

Who this might be right for
Radiotherapy Side EffectNon-small Cell Lung CancerALK Gene Mutation
Karolinska University Hospital 70
Early research (Phase 1)Active Not RecruitingNCT04013542
What this trial is testing

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Who this might be right for
ALK Gene RearrangementEGFR Gene MutationLocally Advanced Lung Non-Small Cell Carcinoma+9 more
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Looking for participantsNCT05014464
What this trial is testing

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 90
Early research (Phase 1)Study completedNCT05055232
What this trial is testing

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Who this might be right for
ROS1 Rearrangement Non-small Cell Lung CancerALK Rearrangement Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 114
Not applicableAvailableNCT04146571
What this trial is testing

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK Gene Rearrangement Positive
Xcovery Holdings, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04644315
What this trial is testing

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Who this might be right for
NeoplasmsColorectal NeoplasmsMelanoma+25 more
Hoffmann-La Roche 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Large-scale testing (Phase 3)Looking for participantsNCT05236946
What this trial is testing

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who this might be right for
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital 190
Early research (Phase 1)Ended earlyNCT04005144
What this trial is testing

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Who this might be right for
ALK Gene RearrangementLung Non-Small Cell CarcinomaProgressive Disease+6 more
University of California, San Francisco 3
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Load More Results